Changes in Hong Kong stocks | Innovative Pharmaceuticals Continues Recent Gains Intensive Foreign Investment, Chinese Innovative Pharmaceutical Companies and Institutions Are Optimistic About the Return of Core Asset Values in the Second Half of the Year

The Zhitong Finance App learned that Innovative Pharmaceuticals continued its recent gains. As of press release, Sihuan Pharmaceutical (00460) rose 8% to HK$1.62; Heplatinum Pharmaceutical-B (02142) rose 7.26% to HK$15.8; Hengrui Pharmaceuticals (01276) rose 6.46% to HK$85.7; Pharmaceuticals (02268) rose 5.46% to HK$64.65; Federal Pharmaceuticals (03933) rose 5.23% to HK$17.3; Shiyao Group (01093) 1%, report HK$11.17.

According to the news, recently, foreign investors have been intensively listing innovative Chinese pharmaceutical companies. According to documents disclosed by the Hong Kong Stock Exchange, on August 29, the Singapore Government Investment Corporation (GIC) increased its shareholding of 402.22 million shares of Hwo Platinum Pharmaceuticals, with an average price of HK$12.7133 per share, worth approximately HK$511 million. After the increase in holdings, the latest number of shares held by the Singapore Government Investment Corporation was 53.97 million shares, and the good position ratio increased from 1.62% to 6.37%. Previously, on August 18, GIC used HK$635 million to buy 80.4 million shares of Cornerstone Pharmaceuticals, and its shareholding increased to 5.49%; on August 26, BlackRock listed Sansheng Pharmaceuticals, with a shareholding ratio of 5.1%.

It is worth mentioning that since this year, the domestically produced innovative drug BD has grown rapidly. According to Huatai Securities, since the beginning of the year, domestic innovative drugs have reached 83 external authorizations, involving a total amount of US$84.531 billion and a down payment of US$4.321 billion. Guojin Securities pointed out that looking forward to next week, the 2025 World Lung Cancer Conference (WCLC) will be held from September 6 to 9. At this conference, there were 35 oral reports from Chinese scholars, and the disclosure of clinical data on new domestic drugs is worth looking forward to. China Post Securities, on the other hand, said it is optimistic that the value of core assets will return in the second half of the year.